Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis.
Drugs: gastrointestinal system
Gastroenterology
Gastrointestinal system
Inflammatory bowel disease
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
24 Oct 2023
24 Oct 2023
Historique:
pmc-release:
24
10
2025
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
25
10
2023
Statut:
epublish
Résumé
We present a patient with a drug-induced liver injury with autoimmune features as a result of infliximab therapy for ulcerative colitis. This is a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of liver function test derangement.
Identifiants
pubmed: 37879703
pii: 16/10/e254272
doi: 10.1136/bcr-2022-254272
pmc: PMC10603518
pii:
doi:
Substances chimiques
Infliximab
B72HH48FLU
Gastrointestinal Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JPS has received speaker fees from AbbVie, Fresenius Kabi, Galapagos, Janssen-Cilag, Pharmacosmos, Takeda and Tillotts Pharma. He has received advisory board fees from AbbVie, Bristol Myers Squibb, Dr Falk Pharma and Galapagos.